NCT07470840

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

A Phase II Multicenter Study of Stereotactic Body Radiation Therapy (SBRT) Combined With Anlotinib and Bimepolizumab in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.

Conditions

• Locally Advanced or Metastatic Renal Cell Carcinoma

Interventions

Type	Name	Description
RADIATION	Stereotactic Body Radiation Therapy (SBRT)	Dose fractionation: 39-48Gy/3f or 40-50Gy/5f, alternative 20-50Gy/5f if OAR dose-limited. Dose adjusted per radiation toxicities during treatment.
DRUG	Anlotinib	Oral anti-angiogenic agent, 12 mg qd fasting, 21d/cycle (2w on/1w off)
DRUG	Bemarituzumab	Intravenous PD-1 inhibitor, 1200 mg q3w, 60min infusion

Timeline

• Start date: 2027-02-01
• Primary completion: 2029-02-01
• Completion: 2029-06-01
• First posted: 2026-03-13
• Last updated: 2026-03-24

Locations

1 site across 1 country: China